VJHemOnc Podcast iwNHL Session IV: T-cell therapies for NHL: CAR-T therapies & third-party EBV T-cells
Nov 30, 2022
Guest
Catherine Bollard, MBChB, MD, FRACP, FRCPA, Children’s National Health System, Washington, DC
Guest
Jeremy Abramson, MD, Massachusetts General Hospital Cancer Ce
Catherine Bollard and Jeremy Abramson discuss T-cell therapies for NHL, including CAR-T therapies and third-party EBV T-cells. They explore real-world data on CD19-directed CAR-Ts and the potential of CD30, CD20, and CD5-directed CAR-Ts in T-cell lymphomas. Topics include safety and efficacy comparisons of different therapies, prescribing patterns, advancements in T-cell therapies, overcoming challenges in CAR-T development, and targeting antigens beyond CD19.
Chapters
Transcript
Episode notes
1 2 3 4 5
Introduction
00:00 • 6min
Comparing the Safety and Prescription of T-cell Therapies
05:51 • 2min
Advancements in T-cell Therapies for NHL: CD19 and CD30 CAR T-cells
07:23 • 3min
Developing CAR T-cell therapies for T-cell malignancies and overcoming challenges
10:47 • 4min
Advancements in CAR T-cell Therapies for NHL: Targeting CD5 and CD7 Antigens
15:02 • 3min